Literature DB >> 12074836

Effects of ablation of N- and R-type Ca(2+) channels on pain transmission.

Hironao Saegusa1, Yoshihiro Matsuda, Tsutomu Tanabe.   

Abstract

Recently several mutant mouse lines lacking neuronal voltage-dependent Ca(2+) channels (VDCCs) have been established by the use of gene targeting in embryonic stem cells. Pain-related behaviors in Ca(v)2.2 (alpha(1B)) and Ca(v)2.3 (alpha(1E)) knockout mice were studied to gain further insight into the mechanism of pain transmission, where VDCCs are thought to play important roles. We review here the data from these recent studies. Ca(v)2.3-/- mice showed normal responses to acute painful stimuli, and reduced responses to the somatic inflammatory pain stimuli. Ca(v)2.3+/- mice exhibited reduced symptoms of visceral inflammatory pain. Ca(v)2.3-/- mice showed abnormal behavior related to the descending antinociceptive mechanism activated by the intraperitoneal injection of acetic acid. Ca(v)2.2-/- mice showed variable acute nociceptive responses depending on the mutant lines. However, all the lines of Ca(v)2.2-/- mice exhibited reduced responses in the phase 2 of the formalin test, suggesting a suppression of inflammatory pain. Furthermore Ca(v)2.2-/- mice showed markedly reduced neuropathic pain symptoms after spinal nerve ligation. Impaired antinociception, similar to that seen in the Ca(v)2.3-/- mice, was also observed in the Ca(v)2.2-/- mice. Therefore, it is suggested that these mutant mice could provide novel models to delineate the nociceptive and antinociceptive mechanisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12074836     DOI: 10.1016/s0168-0102(02)00017-2

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  27 in total

1.  SO-3, a new O-superfamily conopeptide derived from Conus striatus, selectively inhibits N-type calcium currents in cultured hippocampal neurons.

Authors:  Lei Wen; Sheng Yang; Haifa Qiao; Zhenwei Liu; Wenxia Zhou; Yongxiang Zhang; Peitang Huang
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 2.  Neuronal calcium channels: splicing for optimal performance.

Authors:  Annette C Gray; Jesica Raingo; Diane Lipscombe
Journal:  Cell Calcium       Date:  2007-05-18       Impact factor: 6.817

Review 3.  Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.

Authors:  Terrance P Snutch
Journal:  NeuroRx       Date:  2005-10

4.  Regulation of spinal substance p release by intrathecal calcium channel blockade.

Authors:  Toshifumi Takasusuki; Tony L Yaksh
Journal:  Anesthesiology       Date:  2011-07       Impact factor: 7.892

5.  Domain III regulates N-type (CaV2.2) calcium channel closing kinetics.

Authors:  Viktor Yarotskyy; Guofeng Gao; Blaise Z Peterson; Keith S Elmslie
Journal:  J Neurophysiol       Date:  2011-12-28       Impact factor: 2.714

Review 6.  Pain channelopathies.

Authors:  Roman Cregg; Aliakmal Momin; Francois Rugiero; John N Wood; Jing Zhao
Journal:  J Physiol       Date:  2010-02-08       Impact factor: 5.182

7.  Alternative splicing in the C-terminus of CaV2.2 controls expression and gating of N-type calcium channels.

Authors:  Andrew J Castiglioni; Jesica Raingo; Diane Lipscombe
Journal:  J Physiol       Date:  2006-07-20       Impact factor: 5.182

8.  Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons.

Authors:  Xian Xuan Chi; Brian S Schmutzler; Joel M Brittain; Yuying Wang; Cynthia M Hingtgen; Grant D Nicol; Rajesh Khanna
Journal:  J Cell Sci       Date:  2009-11-10       Impact factor: 5.285

Review 9.  Targeting voltage-gated calcium channels for neuropathic pain management.

Authors:  Danielle Perret; Z David Luo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

10.  Custom distinctions in the interaction of G-protein beta subunits with N-type (CaV2.2) versus P/Q-type (CaV2.1) calcium channels.

Authors:  Heather L Agler; Jenafer Evans; Henry M Colecraft; David T Yue
Journal:  J Gen Physiol       Date:  2003-06       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.